Connect
← Return to Video Q&A about Amyloidosis – What Patients Need to Know
Event
Video Q&A about Amyloidosis – What Patients Need to Know
Event Date: June 4, 2015 | 12:00pm - 1:00pm ET
Comment receiving replies
NEOD001 treatment is protein specific. How far behind will trials/ development of the drug for TTR-WILD BE?
Replies to "NEOD001 treatment is protein specific. How far behind will trials/ development of the drug for TTR-WILD..."
Connect
The development of monoclonal antibodies for TTR has been reported, but I am not aware of any clinical trials at this time. Hopefully this might be an option, but will probably be at least a few years down the road.